¼¼°èÀÇ ¹ÙÀÌ·¯½º º¤ÅÍ Á¦Á¶ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, ¿¹Ãø : À¯Çü, Áúȯ, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2025-2033³â)
Viral Vector Manufacturing Market Size, Share, Trends and Forecast by Type, Disease, Application, End User, and Region, 2025-2033
»óǰÄÚµå : 1722870
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 146 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,130,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,507,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 6,884,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¹ÙÀÌ·¯½º º¤ÅÍ Á¦Á¶ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 14¾ï 6,960¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â¿¡´Â 85¾ï 1,220¸¸ ´Þ·¯¿¡ ´ÞÇϰí, 2025-2033³â 21.6%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ÇöÀç ºÏ¹Ì°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, 2024³â ½ÃÀå Á¡À¯À²Àº 49.3% ÀÌ»ó¿¡ ´ÞÇß½À´Ï´Ù. À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, À¯ÀüÀÚ Ä¡·áÀÇ Ã¤Åà Ȯ´ë, ÷´Ü »ý¸í°øÇÐ ÀÎÇÁ¶ó, ÀÓ»ó½ÃÇè È®´ë, °­·ÂÇÑ Á¤ºÎ ÀÚ±Ý Áö¿ø, Ȱ¹ßÇÑ R&D ÅõÀÚ, ÁÖ¿ä ±â¾÷ÀÇ Á¸Àç°¡ ºÏ¹Ì ¹ÙÀÌ·¯½º º¤ÅÍ Á¦Á¶ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

¹ÙÀÌ·¯½º º¤ÅÍ´Â ºÐÀÚ»ý¹°ÇÐÀÚµéÀÌ ¼¼Æ÷ ³»¿¡ À¯Àü¹°ÁúÀ» Àü´ÞÇϱâ À§ÇØ »ç¿ëÇÏ´Â µµ±¸ÀÔ´Ï´Ù. À¯ÀüÀÚ ÁúȯÀ» Ä¡·áÇϱâ À§ÇØ °áÇÔÀÌ ÀÖ´Â À¯ÀüÀÚ¸¦ ´ëüÇϰųª, ÀÚ¿¬ °¨¿°À» ¸ð¹æÇÏ¿© ¸é¿ª ¹ÝÀÀÀ» ÀÏÀ¸Å°±â À§ÇØ º´¿ø¼º Ç׿øÀ» ¹ßÇö ¹× Á¦½ÃÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. Á¾¾ç ¼¼Æ÷¸¦ Ç¥ÀûÀ¸·Î »ï¾Æ »ç¸ê½ÃŰ´Â Á¾¾ç ¿ëÇØ ¿ä¹ý¿¡µµ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ ½ÉÀåÁúȯ, ´ë»ç¼º Áúȯ, ½Å°æÅðÇ༺ Áúȯ µî ´Ù¾çÇÑ ÁúȯÀÇ Ä¡·á¿¡ µµ¿òÀÌ µÇ±â ¶§¹®¿¡ »ý¸í°úÇÐ ¿¬±¸, À¯ÀüÀÚ Ä¡·á, ¹é½ÅÇÐ µî¿¡µµ Æø³Ð°Ô ÀÀ¿ëµÇ°í ÀÖ½À´Ï´Ù. ÇöÀç ¹ÙÀÌ·¯½º º¤ÅÍ Á¦Á¶´Â À¯ÀüÀÚ µ¹¿¬º¯ÀÌ ¹× ü³» ¿°»öü ¼Õ»óÀ¸·Î ÀÎÇÑ À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¸¦ ÀÌÀ¯·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¹ÙÀÌ·¯½º º¤ÅÍ Á¦Á¶ ½ÃÀå µ¿Çâ :

¾ËÄÚ¿Ã ¼Òºñ Áõ°¡¿Í °³ÀÎÀÇ ÁÂ½Ä »ýȰ·Î ÀÎÇÑ ¾Ï ȯÀÚ Áõ°¡´Â ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, Àü ¼¼°èÀûÀ¸·Î ¹ÙÀÌ·¯½º º¤ÅÍ¿¡ ´ëÇÑ ÀÓ»ó ¿¬±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ½Å±Ô ¾à¹° Àü´Þ¿¡ ÀÖ¾î ¹ÙÀÌ·¯½º º¤ÅÍÀÇ »ç¿ë Áõ°¡¿Í ÇÔ²² ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ ¹ÙÀÌ·¯½º º¤ÅÍ´Â ¹ÙÀÌ·¯½º ºñȰ¼ºÈ­ ¼­¿­ÀÇ È¿À²ÀûÀÎ ¿î¹Ýü·Î¼­ Àΰ£ Á¶Ç÷¸ð¼¼Æ÷(HSCs)¿¡ HIV ¾ïÁ¦ µµÀÔ À¯ÀüÀÚ¸¦ Àü´ÞÇÏ´Â µ¥ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀϺΠ±¹°¡ Á¤ºÎ´Â ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å¿¡ ´ëÇÑ »ç¶÷µéÀÇ ÀνÄÀ» ³ôÀ̱â À§ÇØ Ä·ÆäÀÎÀ» ½ÃÀÛÇß½À´Ï´Ù. ¶ÇÇÑ, ½ÂÀÎ ÀýÂ÷ÀÇ ½Å¼ÓÈ­ µî ±ÔÁ¦ ȯ°æÀÇ °³¼±µµ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷µéÀº Àü ¼¼°èÀûÀ¸·Î Á¦Á¶ ¿ª·® °­È­¸¦ À§ÇØ Àû±ØÀûÀ¸·Î ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌµé ±â¾÷µéÀº ÀμöÇÕº´(M&A)¿¡ Àû±ØÀûÀ¸·Î ³ª¼­°í ÀÖÀ¸¸ç, ÀÌ´Â Àüü ¸ÅÃâ°ú ¼öÀͼº Çâ»ó¿¡ µµ¿òÀÌ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­·Ð

Á¦5Àå ¼¼°èÀÇ ¹ÙÀÌ·¯½º º¤ÅÍ Á¦Á¶ ½ÃÀå

Á¦6Àå ½ÃÀå ºÐ¼® : À¯Çüº°

Á¦7Àå ½ÃÀå ºÐ¼® : Áúȯº°

Á¦8Àå ½ÃÀå ºÐ¼® : ¿ëµµº°

Á¦9Àå ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

Á¦11Àå SWOT ºÐ¼®

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå PorterÀÇ Five Forces ºÐ¼®

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global viral vector manufacturing market size was valued at USD 1,469.6 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 8,512.2 Million by 2033, exhibiting a CAGR of 21.6% from 2025-2033. North America currently dominates the market, holding a market share of over 49.3% in 2024. The rising prevalence of genetic disorders, increasing adoption of gene therapies, advanced biotechnology infrastructure, expanding clinical trials, strong government funding, robust R&D investments, and the presence of leading pharmaceutical companies drive the viral vector manufacturing market in North America.

A viral vector is a tool used by molecular biologists for delivering genetic materials into cells. It is used to replace defective genes for curing genetic disorders and express and present pathogenic antigens for generating an immune response by mimicking a natural infection. It is widely employed in oncolytic therapies to target and kill tumor cells. Besides this, as it assists in treating different diseases, such as heart defects, metabolic diseases, and neurodegenerative disorders, it finds extensive applications in life science research, gene therapy and vaccinology. At present, there is a rise in viral vector manufacturing on account of the rising prevalence of genetic disorders due to a combination of gene mutations and damaged chromosomes in the body.

Viral Vector Manufacturing Market Trends:

The increasing cancer patients due to the rising alcohol consumption and sedentary lifestyles of individuals represents one of the key factors contributing to the growth of the market. In addition, there is a rise in the number of clinical studies undertaken on viral vectors across the globe. This, along with the growing utilization of viral vectors in novel drug delivery, is positively influencing the market. Besides this, they are efficient carriers of virus-disabling sequences and are used to deliver HIV-inhibiting transgenes to human hematopoietic stem cells (HSCs). Additionally, governments of several countries are launching campaigns to generate awareness about viral vector vaccines among individuals. They are also improving the regulatory environment via changes, such as fast-track approval processes. Furthermore, key market players are extensively investing in capacity expansion for manufacturing activities around the world. These players are also indulging in mergers and acquisitions (M&A), which is projected to increase their overall sales and profitability.

Key Market Segmentation:

Breakup by Type:

Breakup by Disease:

Breakup by Application:

Breakup by End User:

Breakup by Region:

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi S.A., Thermo Fisher Scientific Inc. and uniQure N.V.

Key Questions Answered in This Report

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Viral Vector Manufacturing Market

6 Market Breakup by Type

7 Market Breakup by Disease

8 Market Breakup by Application

9 Market Breakup by End User

10 Market Breakup by Region

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Price Analysis

15 Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â